By Fineline Cube 
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE: 002399, HKG: 9989) has announced that it has received marketing approval from South Africa’s Health Products Regulatory Authority (SAHPRA) for its enoxaparin sodium injection (brand name: Prolongin). The approval covers five dosage strengths: 0.2ml:20mg, 0.4ml:40mg, 0.6ml:60mg, 0.8ml:80mg, and 1.0ml:100mg.
Product and Indications
Ivenoxin, a low molecular weight heparin product, is approved for use in thromboprophylaxis in surgical settings (pre- and post-operative), prevention of thromboembolism in acutely ill patients with restricted mobility, treatment of established deep vein thrombosis (DVT), reduction of cardiovascular complications when co-administered with aspirin in unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI), and prevention of clotting in extracorporeal circuits during hemodialysis.-Fineline Info & Tech